Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment

Onyx Health

- PMLiVE

Evoke KYNE promotes Michael Grela to head of reputation and social impact

Newly established role creates new in-house speciality area at agency

- PMLiVE

Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration

Partners will join forces to develop new therapeutics for brain diseases and CNS disorders

- PMLiVE

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

Detailed results from the NAVIGATOR trial presented at virtual AAAAI meeting

- PMLiVE

J&J’s one-dose COVID-19 vaccine granted emergency use approval by FDA

Company has already started shipping doses of the vaccine to the US

- PMLiVE

Building meaningful customer engagement through data-driven digital insights

Understanding the helpful insights that online HCP conversations can reveal

- PMLiVE

Rare Disease Day in a COVID-19 environment

For many people and families living with a rare disease, their journey can be very complex. At times, that journey can even be scary, frustrating and confusing. However, when your...

Lucid Group Communications Limited

- PMLiVE

FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine

Vaccine can be transported/stored at standard pharmaceutical freezer temperatures

- PMLiVE

The five-step, rare disease-ready checklist

How can a commercial team find success in the rare disease area?

- PMLiVE

bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video

Personal stories from nine patients from seven European countries, aged between 4 and 61, shed light on the impact of living with thalassaemia

regeneron headquarters

UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

CHMP has now adopted a positive opinion for the treatment

- PMLiVE

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links